Oystein Rekdal

Oystein Rekdal serves as Chief Executive Officer at Lytix Biopharma. Lytix Biopharma operates in the biotechnology sector with approximately 22.0 employees. The company is headquartered in Oslo, Oslo. Lytix Biopharma generates annual revenue of 2400000.0.

Industry & Role Insights

• • MessageCEO tracks 381 executives in the biotechnology sector.
• • 1,203 executive contacts are available in Oslo.
• • Our database includes 201,468 c suite-level executives.

Cloudflare DNS Outlook Microsoft Office 365 Google Font API Google Maps Nginx Vimeo Mobile Friendly Bootstrap Framework reCAPTCHA Google Maps (Non Paid Users)

biotech cancer treatment immunotherapy host-defense peptides tumor heterogeneity t-cell response clinical-stage combination therapy molecular technology cancer immunology therapeutics antigen presentation tumor antigens peptide chemistry resistant cancer cells immune system activation biopharmaceuticals drug development oncology clinical trials preclinical studies immune modulation drug discovery research collaborations biotech investments imet cytokines peer-reviewed publications biotech platform strategic business development clinical programs partnering strategies pharmaceutical collaborations r&d science & technology life sciences financial reports shareholder information euronext growth investor relations clinical data drug efficacy cancer indications risk assessment safety profiles patient outcomes hospital & health care health care health wellness & fitness research & development

CB

Chip Baird Chief Executive Officer at 2seventy bio at 2seventy bio

JL

Jason Loveridge CEO at 4SC AG

MM

Marie Moores Chief Operating Officer at AB Cavalli Coach & Consultant

JR

Julie Rubinstein President and Chief Operating Officer at Adaptive Biotechnologies Corp.

CH

Chris Harano President and CEO at Advanced BioCatalytics

Outreach Guidance — biotechnology Sector

Technology executives make decisions on infrastructure, tooling, and partnerships. When reaching out to Oystein Rekdal, lead with your value proposition relative to the stack they currently use. Generic pitches perform poorly; specific technical relevance is key.

Oystein Rekdal's Position in the MessageCEO Database

• •Oystein Rekdal is 1 of 1 verified executive contact we track at Lytix Biopharma.
• •365 verified executive contacts in biotechnology are in the MessageCEO database.
• •1,199 verified executive contacts in Oslo are in the database.
• •18 verified contacts work at biotechnology companies in the 22.0 employee range (same size as Lytix Biopharma).

Executive contact data compiled from public business filings, LinkedIn public profiles, company press materials, and verified outbound email testing. We do not publish personal addresses or sensitive identifiers. Methodology & sources · Removal requests handled at /remove-info · Updated July 2026.

How do I reach Oystein Rekdal directly?

Oystein Rekdal's verified email address is available to MessageCEO Pro subscribers. They currently serve as Chief Executive Officer at Lytix Biopharma. Access direct contact info to skip gatekeepers and reach the decision maker.

What company does Oystein Rekdal work for?

Oystein Rekdal is Chief Executive Officer at Lytix Biopharma, a company in the biotechnology sector with 22.0 employees. The company is based in Oslo, Oslo.

Can I pitch or sell to Oystein Rekdal?

As Chief Executive Officer at Lytix Biopharma, Oystein Rekdal is a key decision-maker in the biotechnology sector. MessageCEO Pro gives you verified email to reach Oystein Rekdal directly — ideal for B2B sales, partnerships, and executive recruiting.

What industry is Oystein Rekdal in?

Oystein Rekdal works in the biotechnology industry as Chief Executive Officer at Lytix Biopharma. MessageCEO provides verified contact information for executives across all major industries.

Is Oystein Rekdal's contact information verified?

Yes. MessageCEO verifies executive contact information through multiple data sources and regular validation checks. Oystein Rekdal's profile is kept up-to-date with the latest available information.

Last updated: July 29, 2026